Last reviewed · How we verify
Chronic non-neuropathic Gaucher's disease
Approved treatments
- glucocerebrosidase · National Center for Research Resources (NCRR)
- Ceredase · Sanofi
- Vpriv · Shire Human Genetic
VELAGLUCERASE ALFA replaces the deficient enzyme glucocerebrosidase in patients with Gaucher's disease.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Chronic non-neuropathic Gaucher's disease patent landscape — cliff calendar, originator estates, attackable patents
- Chronic non-neuropathic Gaucher's disease treatment landscape brief
- Chronic non-neuropathic Gaucher's disease treatment updates RSS
Frequently asked questions about Chronic non-neuropathic Gaucher's disease
What drugs treat Chronic non-neuropathic Gaucher's disease?
Tracked treatments include glucocerebrosidase, Ceredase, Vpriv.
What is the treatment for Chronic non-neuropathic Gaucher's disease?
Standard treatment for Chronic non-neuropathic Gaucher's disease includes glucocerebrosidase, Ceredase, Vpriv. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Chronic non-neuropathic Gaucher's disease patent cliff · Chronic non-neuropathic Gaucher's disease CI report
- Treatment: glucocerebrosidase · National Center for Research Resources (NCRR)
- Treatment: Ceredase · Sanofi
- Treatment: Vpriv · Shire Human Genetic
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing